Unload. Rest. Recover.
Did you know...?
...that the Impella platform is proven to increase survival in cardiogenic shock as well as hemodynamic effects during VA ECMO support.
Designed for Cardiac Surgeons
The Impella 5.5® with SmartAssist® heart pump is designed for surgeons who want to offer their patients complete left ventricular unloading with full systemic flow. Here you can find all information about the Impella 5.5 with SmartAssist heart pump. It is applied via the axillary artery or directly via the aorta using common surgical methods. In doing so, it results in direct unloading of the left ventricle by reducing ventricular work for a period of up to 30 days. The Impella 5.5 with SmartAssist heart pump is used, for example, in patients with cardiogenic shock.
-
2x
higher survival rate exists with ECMO therapy with Impella® heart pump1
-
82%
Improved chances of survival2,3,4
-
36%
Lower relativ risk of 30-day mortality due to early active LV unloading
Improving Outcomes with ECpella Therapy
Learn more about Impella heart pumps in combination with VA-ECMO - ECPella.
How Does Escalation Relate to Therapy Options Using Impella Heart Pumps?
In the context of therapy options with Impella heart pumps, "escalation" refers to the process of gradually increasing the level of support provided by the device in response to the patient's changing clinical needs.
Postcardiotomy Cardiogenic Shock (PCCS)
Postcardiotomy cardiogenic shock (PCCS) is a rare but potentially life-threatening complication that can occur after cardiac surgery. Learn more about risk factors and the role of Impella heart pumps.
Impella 5.5® with SmartAssist® Heart Pump
A heart pump designed for surgeons with forward flow and intelligent patient management.
Impella CP® with SmartAssist® Heart Pump
Discover the next generation of heart recovery.
Download Additional Ressources
Learn more about the hemodynamic effects in the context of the ECpella concept.
Download NowContact Us
Do you want to learn more about Impella heart pumps? Contact us and get in touch with your dedicated Abiomed representative.
References
- Pappalardo et al (2017) Eur J Heart Failure, 19 (3), 404-412
- Ako, et al. (2022). TCT Symposium.
- Available U.S. publications and FDA studies with device-specific rates of major bleeding or bleeding requiring transfusion
- Panoulas et al. (2021) Rev Cardiovasc Med., DOI: 10.31083/j.rcm2204154
First 11,203 Completed Cases as of July 19, 2023, Excludes Unknown Outcomes, IQ Database / Remaining Patients Categorized as Myocarditis & Other Off-Label Uses, Not Reflected in the Data Shown
NPS-3519